{"disease":{"id":"recurrent-epithelial-cancer-of-ovary","name":"recurrent epithelial cancer of ovary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT03312114","title":"Anti-PD-L1 and SAbR for Ovarian Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}